Search

Author/Creator Gamba, Sebastian

1. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Issue 4 (April 2015)

Authors:
Gamba, Sebastian; Camaj, Peter; Heinemann, Volker; Laubender, Rüdiger P.; Wang, Yan; Zhao, Yue; Stintzing, Sebastian; Giessen, Clemens; Boeck, Stefan; Haertl, Christoph; Bruns, Christiane J.; Modest, Dominik P.
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 4(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Issue 4 (April 2015)

Authors:
Gamba, Sebastian; Camaj, Peter; Heinemann, Volker; Laubender, Rüdiger P.; Wang, Yan; Zhao, Yue; Stintzing, Sebastian; Giessen, Clemens; Boeck, Stefan; Haertl, Christoph; Bruns, Christiane J.; Modest, Dominik P.
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 4(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. (July 2015)

Authors:
Camaj, Peter; Primo, Stefano; Wang, Yan; Heinemann, Volker; Zhao, Yue; Laubender, Ruediger Paul; Stintzing, Sebastian; Giessen-Jung, Clemens; Jung, Andreas; Gamba, Sebastian; Bruns, Christiane Josephine; Modest, Dominik Paul
Journal:
Future oncology
Issue:
Volume 11:Number 13(2015)
Page Start:
1919
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗